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Background: In 1996, Brazil became the first developing country to provide free, universal access to HAART,
laboratory monitoring, and clinical care to any eligible patient. As of June 2014, approximately 400,000 patients
were under treatment, making it the most comprehensive HIV treatment initiative implemented thus far in a
middle-income country, worldwide. The Brazilian epidemic is highly concentrated among men who have sex with
men (MSM).
Methods: Four national information systems were combined and Cox regression was used to conduct
retrospective cohort analysis of HAART availability/access on all-cause mortality among MSM diagnosed with AIDS
reported to the information systems between 1998–2008, adjusting for demographic, clinical, and behavioral factors
and controlling for spatially-correlated survival data by including a frailty effect. Multiple imputation by chained
equations was used to handle missing data.
Results: Among 50,683 patients, 10,326 died during the 10 year of period. All-cause mortality rates declined
following introduction of HAART, and were higher among non-white patients and those starting HAART with higher
viral load and lower CD4 counts. In multivariable analysis adjusted for race, age at AIDS diagnosis, and baseline CD4
cell count, MSM diagnosed in latter periods had almost a 50% reduction in the risk of death, compared to those
diagnosed between 1998–2001 (2002–2005 adjHR: 0.54, 95% CI:0.51-0.57; 2006–2008 adjHR: 0.51, 95% CI:0.48-0.55).
After controlling for spatially correlated survival data, mortality remained higher among those diagnosed in the
earliest diagnostic cohort and lower among non-white patients and those starting HAART with higher viral load
and lower CD4 lymphocyte counts.
Conclusions: Universal and free access to HAART has helped achieve impressive declines in AIDS mortality in Brazil.
However, after a 10-years follow-up, differential AIDS-related mortality continue to exist. Efforts are needed to identify
and eliminate these health disparities, therefore improving the Brazilian response towards HIV/AIDS epidemic.
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By the end of 2013, 35 million [33.2 million-37.2 million]
people were living with HIV worldwide and 1.5 million
[1.4 million-1.7 million] AIDS-related deaths were re-
ported in the latest Epidemiological Bulletin released by
UNAIDS. The introduction of combination antiretroviral
therapies has led to dramatic improvements in AIDS-
related morbidity and mortality in countries where this
treatment is available [1].
Highly active antiretroviral therapy (HAART) signifi-
cantly improves the prognosis of HIV-infected persons
by reducing HIV viral load, increasing CD4+ lymphocyte
counts and delaying progression to AIDS, ultimately re-
ducing mortality rates [2,3].
Pre-exposure prophylaxis (PrEP) for HIV infection has
greatly improved the field of HIV prevention [4], and a
recent systematic review suggests its efficacy among
high-risk groups such as men who have sex with men –
MSM [5].
Early detection and management of HIV infection are
key challenges worldwide, but a growing body of evi-
dence supports the immediate use of HAART to main-
tain CD4 count and functionality, limit the size of the
HIV reservoir, and reduce the risk of onward viral trans-
mission [6]. Following such groundbreaking results,
Brazil has recently announced plans to adopt the “Treat-
ment as Prevention” strategy to curb HIV and AIDS [7].
However, AIDS-related deaths continue to occur, even
in high-income countries, and the emergence of drug-
resistant HIV variants and drug toxicities remain major
barriers and challenges to successful long-term anti-
retroviral efficacy [8,9].
Although stable, on average, the epidemic in Central
and South America is currently concentrated in specific
groups, mainly among MSM [1,10]. In Brazil MSM
accounted for more than 32% of the cumulative reported
cases of AIDS from 1980 to 2010 among men older than
13 years of age [11]. Data from a Brazilian meta-analysis
indicated a pooled HIV prevalence of 13.6% (95% CI:8.2-
20.2) among MSM [12]. National data from sexually
transmitted infections’ clinics in Brazil demonstrated a
1.7% overall prevalence for HIV among clinic attendees
[11]. However, when stratified for subgroups defined by
sexual exposure, prevalence among MSM was found to
be 5.7%, compared to 1.1% among heterosexual men.
Data from three voluntary counseling and testing ser-
vices reported 24.8% prevalence among MSM and 4.3%
among heterosexual men [13]. HIV incidence at VCT
units in Rio de Janeiro, Brazil, indicated incidence up to
11 times higher among MSM when compared to hetero-
sexual men [13,14].
Brazil was the first middle-income country to provide
full access to HAART, laboratory monitoring and clinical
care at no cost at the point of health care delivery to anyeligible patient, since 1996 [15]. As of June 2014, ap-
proximately 400,000 patients were receiving HAART in
Brazil [11], making it the most comprehensive HIV
treatment initiative implemented thus far in a middle-
income country, worldwide [16].
Recent Brazilian observational studies have brought
essential information about mortality patterns among
HIV-positive patients under follow-up in Brazil’s referral
centers [17,18]. However, clinical cohorts from selected
referral centers do not assess real-life conditions found
in busy, understaffed public health clinics scattered all
over Brazil, a country where social and regional hetero-
geneities are very relevant in the field of AIDS care
[19,20], as well as health care in a broad sense [21].
Herein, we report differences in survival from AIDS
diagnosis according to period of AIDS diagnosis, within
the unique Brazilian setting. The study evaluated all
MSM receiving treatment in the country between 1998
and 2008, therefore avoiding selection bias present in
analyses from specific subsets (such as referral centers
from major southeastern metropolitan areas, particularly
Rio de Janeiro and Sao Paulo) of the country’s popula-
tion living with HIV/AIDS.
Methods
This study utilized four databases comprising different
longitudinal information of all people living with HIV/
AIDS (PLWHA) under treatment and care through the
Brazilian public health system. These databases comprise
all patients receiving any antiretroviral medicine in
Brazil since such medicines are not procured, purchased,
or delivered by private health facilities or pharmacies for
patients who are not hospitalized.
These databases contain the core information of Brazil’s
surveillance system. Their basic characteristics are briefly
summarized as follows:
i. Socio-demographic and basic clinical (for the sake of
diagnosis) information on AIDS cases (SINAN-AIDS -
Information System for Notifiable Diseases/AIDS);
ii. Data from exams conducted in the network of
accredited public laboratories, particularly TCD4+/TCD8
lymphocyte counting and HIV viral load (SISCEL -
National Database for Laboratory Tests);
iii. Information about monthly ARV refills and therapeutic
regimen changes over time (SICLOM - Logistics
Control System of ARV Medicines); and
iv. The date and cause/s of death (SIM - National
Mortality Database).
Whereas patients may seek private medical care and
perform laboratory exams in private facilities, all
PLWHA receive their antiretroviral drugs through SUS
(Brazil’s Unified Public Health System), the single
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cluded in SICLOM database. At the time we conducted
our analysis, SICLOM data have been updated to im-
prove the comprehensiveness of collected data, which
tend to be limited to the core information which is es-
sential for medicines dispensing at the several health ser-
vices belonging to the network of accredited public
health units. Thus, to utilize data from all regions, we
could not include additional information such as mea-
sures of adherence, side effects, drug regimen shifts, etc.
as these data were not yet available for all regions and
services.
Data from the entire population of PLWHA with
AIDS diagnosis between 1998 and 2008, whose trans-
mission category was homo/bisexual contact were ex-
tracted from those databanks and merged. The databank
linkage procedures have been described in detail else-
where [15].
For this analysis, participants were included if they
were diagnosed as having AIDS between January 1, 1998
and December 31, 2008, and if their most probable route
of HIV infection was male-male unprotected anal inter-
course. Those patients were included because we aimed
to analyze differences in survival from AIDS diagnosis
among the MSM population, for which higher rates of
initiation and better adherence to HAART during three
different AIDS diagnosis periods: 1998–2001, 2002–
2005, and 2006–2008 have been documented in the lit-
erature and by our own exploratory analyses.
The final merged database comprised the following co-
variates: date of birth, race, date of AIDS diagnosis, dates
of initiation of HAART, CD4 counts and viral load at
diagnosis, cause(s) and date of death. CD4 counts at initial
diagnosis were classified into three categories: < 200 cells/
mm3, 200–350 cells/mm3, and >350 cells/mm3. Viral
load at initial diagnosis was classified as <4.00 log10 cop-
ies, 4.00-5.00 log10 copies, and >5.00 log10 copies.
Statistical analyses
The primary endpoint of interest in the present study
was all-cause mortality during 1998–2008. Survival was
calculated as the time elapsed from date of AIDS diag-
nosis until the date of death. Individuals who remained
alive were censored at the end of data collection period
(December 31, 2008). Time from AIDS diagnosis was
transformed from days to years since diagnosis. Since
analyses were based on secondary data, we did not have
access to information on clinical visits; therefore we
were not able to calculate losses to follow-up.
Kaplan-Meier curves were fitted to compare probabil-
ities of survival according to selected period of diagnosis
and CD4 count at diagnosis using the log-rank test. Cox
proportional hazard regression modeling was used to
examine covariates associated with survival among thefollowing: age at AIDS diagnosis, race, period of AIDS
diagnosis (1998–2001; 2002–2005; 2006–2008), first
CD4+ lymphocyte count, HAART uptake, and first HIV-
RNA viral load exam. The likelihood ratio test was used
to select variables to be entered in the Cox models,
adjusting for potential confounders. The assumption of
proportional hazards was evaluated through the examin-
ation of Schoenfeld residuals [22].
Hazard rates are strongly influenced by selection ef-
fects operating in the population (e.g. higher availability
of referral centers in a given locality), and individuals
surviving up to a certain time will on average be less frail
than the original population, therefore unobserved indi-
vidual heterogeneity (or frailty) was also taken into ac-
count [23].
With 8.5 million square kilometers and over 202 million
inhabitants according to the National Census, 2010, up-
dated as of July 2013 [24] and regular updates issued by
the Brazilian Institute for Geography and Statistics (IBGE),
Brazil is the largest and most populous country in Latin
America, and faces deep health and socio-economic differ-
ences between and within each region. In an attempt to
account for the heterogeneity between and within differ-
ent Brazilian regions and localities, Cox regression ana-
lyses were repeated with the introduction of a random
effect term to assess the potential association between
survival times within a cluster – state or municipality of
residency – using gamma-distributed frailty [23]. A frailty
indicator >1 denotes a faster event (death) rate, while
groups will frailty <1 survival tend to be longer [25].
To estimate confidence intervals for Cox's propor-
tional hazards models, robust methods were used. Max-
imum penalized likelihood estimation was used to fit
frailty models. To handle missing data, we implemented
multiple imputation by chained equations using classifi-
cation and regression trees (MICE-CART) as the condi-
tional models for imputation [26]. This method can
result in more plausible imputations, and hence more
reliable inferences, in complex settings than the naive
application of standard sequential regression imputation
techniques.
Creating multiple imputations, as opposed to single
imputations, accounts for the statistical uncertainty in
the imputations. In addition, the chained equations ap-
proach is very flexible and can handle variables of vary-
ing types (e.g., continuous or binary), and has been
reported as very reliable when used in different datasets
[27,28]. All analyses were performed using R software
version 3.0.2 (library survival) and Stata 13.0 (College
Station, TX) [29].
Ethical approval
No identifiable personal data were used for this study.
The dataset used in the study is not openly available.
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tracted from HIV/AIDS administrative databases was
granted by the Brazilian Ministry of Health, Department
of STDs, AIDS and Viral Hepatitis. Ethical approval for
use of encrypted and aggregated data was also obtained
from the Oswaldo Cruz Foundation Research Ethics
Committee (Protocol CEP/ENSP 179/08) and the Brazilian
National Research Ethics Committee (CONEP 15308).
Results
Characteristics of the patients
Between January 1 1998 and December 31 2008, 50,683
MSM were diagnosed with AIDS in Brazil. Of these,
20,702 (40.9%) were diagnosed between 1998–2001,
19,280 (38.0%) in 2002–2005, and 10,701 (21.1%) in the
last period under analysis, 2006–08. The overall mean
age at AIDS diagnosis was 35.4 years (SD: 9.5). Data on
race from 39.0% of our sample was missing. Although all
patients had a confirmed AIDS (clinical) diagnosis, there
were no information respecting 29.5% of the CD4 counts
and 42.5% HIV-1 RNA viral load determinations in theTable 1 Sociodemographic and clinical characteristics of the s
Tota
Subjects (N, %) 50,6
Follow-up time (person-years) 249,
Age at diagnosis (years)




Mulatto (mixed white and black) 9,29
Black 2,91
Others (Asian, Indigenous…) 307
Unspecified 19,7
Deathsa 10.3
Have at least one CD4 exam available on SISCEL
No 14,9
Yes 35,7
CD4 lymphocytes, cells/mm3 (first exam available)b
Mean ± SD 298.
Range 0 –
Have at least one HIV-1 RNA Viral load exam available on SISCEL
No 21,5
Yes 29,1
HIV RNA in plasma, log10 copies/ml (first exam available)
c
Mean ± SD 4.46
Range 1.70
aAll causes of death; bAmong those with at least one CD4 exam; cAmong those witmerged database (Table 1). Due to the significant amount
of missing data, MICE-CART multiple imputation was
conducted before running survival analysis.
There were 10,326 deaths during the 10 year period.
The median follow-up times for patients in three diagnosis
periods are: period 1998–2001: 8.36 years; period 2002–
2005: 4.68 years; and period 2006–2008: 1.44 years.
In Kaplan-Meier analyses stratified by diagnostic period,
those diagnosed in the first period had significantly lower
survival since AIDS diagnosis (p < 0.0001), with visible
improvements among patients from the second and
third cohort period (p < 0.0001). Taking into consider-
ation the short follow-up time for participants in diag-
nostic period 2006–2008, there appeared to be little
difference in survival between the last two diagnostic
periods (Figure 1).
In the unadjusted analysis, the risk of death was lower
for both periods 2002–2005 (HR: 0.74; 95% CI:0.71-0.77;
p < 0.001) and 2006–2008 (HR: 0.81; 95% CI:0.76-0.86;
p < 0.001), compared to the first period of diagnosis
(1998–2001). The unadjusted HR for the period 2006–2008tudy patients
Diagnostic period
l 1998 − 2001 2002 − 2005 2006 − 2008
83 20,702 19,280 10,701
656.30 149,494.24 84,776.07 15,385.97
± 9.5 35.3 ± 9.2 35.3 ± 9.5 35.8 ± 9.9
89 18 – 89 18 – 86 18 – 85
99 (36.3) 3,087 (14.9) 9,454 (49.0) 5,858 (54.8)
0 (18.3) 1,408 (6.8) 4,701 (24.4) 3,181 (29.7)
2 (5.8) 478 (2.3) 1,520 (7.9) 914 (8.5)
(0.6) 64 (0.3) 132 (0.7) 111 (1.0)
75 (39.0) 15,666 (75.7) 3,473 (18.0) 637 (6.0)
26 5.791 3.258 1.277
34 (29.5) 8.081 (39.0) 4.082 (21.2) 2,771 (25.9)
49 (70.5) 12.621 (61.0) 15.198 (78.8) 7,930 (74,1)
1 ± 185.3 324.8 ± 179.3 289.5 ± 191.7 261.9 ± 177.0
999 0 – 998 0 – 998 0 – 999
62 (42.5) 11,097 (53.6) 6,601 (34.2) 3,864 (36.1)
21 (57.5) 9.605 (46.4) 12,679 (65.8) 6,837 (63.9)
± 1.01 4.38 ± 1.04 4.46 ± 1.02 4.60 ± 0.91
– 6.69 1.70 – 6.67 1.70 – 6.69 1.70 – 6.69
h at least one viral load exam; SISCEL: National Database for Laboratory.
Figure 1 Overall Survival Among MSM in Brazil from 1998–2009
After AIDS Diagnosis, by Period of Diagnosis.
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compared to the reference of 2002–2005 to assess dif-
ference between latter periods (data not shown).
Predictors of survival
Controlling for other variables, the risk of death among
latter cohorts of diagnosis was lower when compared to













CD4 cell count at diagnosis (cells/mm3)
< 200 Reference
200 - 350 0.65*
>350 0.20*





Hazard Ratio (95% Confidence Interval); *p-value < 0.001; Cox proportional hazards
diagnosis in 2006–2008 to the reference of 2002–2005: adjusted HR: 0.95 (95% CI: 0
CI: 0.88 - 0.01; p = 0.085).2005 adjHR: 0.54, 95CI:0.51-0.57; Period 2006–2008
adjHR: 0.51, 95%CI:0.48-0.55). There was no difference
between the cohort diagnosed in 2006–2008 compared
to the cohort diagnosed in 2002–2005, after adjustment
in the Cox model (adjHR: 0.95; 95% CI:0.89-1.02). Add-
itional predictors of longer survival included younger
age at diagnosis and higher CD4 counts at diagnosis.
Patients with an HIV-RNA viral load >5log10 copies/ml
at diagnosis had a higher risk of death, as well as non-
White patients (Table 2).
Upon multivariate Cox frailty regression that accounted
for a random effect associated with the Brazilian state
where patients lived (Table 2), the increased risk of
death observed in patients diagnosed in the first period
of time persisted. Both higher CD4 cells counts and
lower HIV-1 RNA viral load remained as significant pre-
dictors of survival. Non-White patients remained with a
higher risk of death; however, there was no longer a dif-
ference between white participants and those with un-
specified race.
The estimated frailty variance was significantly differ-
ent from zero, suggesting that the risk of death after
AIDS diagnosis was heterogeneous among subjects liv-
ing in different states (Table 2). We adjusted the final
model with and without MICE-CART imputationbles among MSM patients diagnosed with AIDS in Brazil,
Adjusted by state frailty effect
95% CI HR 95% CI
(1.11 - 1.16) 1. 13* (1.11 - 1.16)
Reference
(1.09 - 1.21) 1.29* (1.22 - 1.37)
(0.84 - 0.94) 1.02 (0.96 - 1.08)
Reference
(0.51 - 0.57) 0.55* (0.52 - 0.58)
(0.48 - 0.55) 0.52* (0.49 - 0.56)
Reference
(0.63 - 0.68) 0.67* (0.65 - 0.70)
(0.18 - 0.21) 0.19* (0.17 - 0.20)
Reference
(1.19 - 1.37) 1.22* (1.14 - 1.31)
(4.40 - 4.98) 5.26* (4.94 - 5.61)
— 0.099*
model adjusted for all variables listed in the table. tComparing period of
.89 - 1.02; p = 0.144); model adjusted for state frailty effect: HR: 0.94 (95%
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the results (data not shown).
Greater frailty effects (and therefore greater mortality)
were found in larger states located in the Tropical Rain
Forest region and in states located in the Northeast, Brazil’s
poorest region. On the other hand, industrialized areas
from the Southern and Southeastern regions accounted
for the smallest frailty effect (Figure 2).
Discussion
This is the first Brazilian nationwide analysis of survival
after AIDS diagnosis among MSM. Our study compared
different time periods after the full introduction of
HAART over the whole country, following the approval
of the federal legislation regulating the right to the uni-
versal access to antiretroviral medicines for people living
with AIDS, as of the end of 1996 [29]. Improvements in
survival were observed for latter periods of diagnosis,
with almost 50% reduction in risk of death when com-
pared to the earliest cohort. Protective effects were also
observed with lower age and higher CD4 classifications
at initial diagnosis.
Previous papers documented the dramatic improve-
ment of survival before and after HAART [30], and
identified lower mortality rates among PLWHA from
Brazil, when compared with patients from other LatinFigure 2 Frailty estimates of relative risks of state showing the
point estimate (circle) and a confidence interval of 95%. Both
the interval and the distribution are skewed because the relative
risks in an exponential function of the gamma estimate. Abbreviations:
Acre (AC); Alagoas (AL); Amapá (AP); Amazonas (AM); Bahia (BA); Ceará
(CE); Distrito Federal (DF); Espírito Santo (ES); Goiás (GO); Maranhão
(MA); Mato Grosso (MT); Mato Grosso do Sul (MS); Minas Gerais
(MG); Pará (PA); Paraíba (PB); Paraná (PR); Pernambuco (PE); Piauí
(PI); Rio de Janeiro (RJ) ; Rio Grande do Norte (RN); Rio Grande do
Sul (RS); Rondônia (RO); Roraima (RR); Santa Catarina (SC); São Paulo
(SP); Sergipe (SE); Tocantins (TO).American countries [31]. Changes in the main causes of
death from AIDS to non-AIDS related conditions have
also been identified [18,32], however, those studies were
conducted in a pool of referral centers or in a single refer-
ral center, and none of them assessed nationwide data,
taking in consideration their pronounced heterogeneity.
The observed improvements in the latter periods of
diagnosis compared to those diagnosed between 1998–
2001 are favorable. No difference, however, has yet been
detected between those diagnosed in 2006–2008 com-
pared to those diagnosed in 2002–2005. This finding
may be attributed to barriers and problems in the
current treatment program and the concrete operations
of the respective network of public health services.
Among the most relevant of such challenges, some are
highlighted as follows: i) the increasing pressures over
costs [33], challenging the very sustainability of universal
access over time; ii) the deep heterogeneity of the Brazil-
ian network of health services, either in the specific field
of AIDS management and care [20] or from the perspec-
tive of the health system in a broad sense [21]; and, iii)
last but not the least, the late presentation of a substan-
tial fraction of patients [19]. Nonetheless, it is important
to note that the median follow-up time for patients diag-
nosed in 2006–2008 is substantially shorter and future
research may observe improvements after longer dura-
tions of follow-up of this cohort.
Other problems to be tackled by clinicians and health
managers include the progressive, albeit moderate, in-
crease of secondary resistance [34] and the permanent
challenge posed by side effects of different antiretroviral
medications, such as lipodystrophy and metabolic syn-
dromes [35]. However, despite all such caveats and diffi-
culties, the present paper documents a progressive
increase of survival times among gay men over succes-
sive periods of the decade 1998–2008. Similar findings
were identified by a multi-site study comprising data
from several North American cohorts. According to the
study conducted by Samji and colleagues [29], who ana-
lyzed data from almost 23,000 treatment-naive ART pa-
tients from the MSM population, the life-expectancy at
age 20 years increased with calendar time, from 53.3 in
2000–2002 to 69.3 in 2006–2007. Future Brazilian stud-
ies should include more recent timeframes, as well as
additional information about HAART uptake and treat-
ment adherence.
Conclusions
Our statistical modeling incorporated frailty effects and
demonstrated a pronounced effect of geographic, social
and/or health care quality upon survival times. It is not
possible to disentangle the independent effects of each
one of these factors; however, our study highlighted the
negative impact on survival among patients living in less
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living in such areas are likely to suffer from an adverse
and synergic effect of poverty and lack of social support,
receiving less than optimal care in settings where health
services are scarce, overburdened, less accessible and of
lower quality [21].
As in any analysis of large secondary datasets, there is
a trade-off between the augmented comprehensiveness
of patient data under analysis and the deficiencies in
terms of coverage and quality of databases. In this sense,
the missing information identified in the current study
constitutes serious limitations, not only in terms of the
resulting analyses, but also from the broader perspective
of monitoring and policymaking.
Such barriers and caveats must be progressively over-
come by policymakers, managers, health professionals
and the civil society in a continental-sized, deeply het-
erogeneous country, housing the most comprehensive
network of ARV dispensing units worldwide. With in-
creasing costs and the pressing need to switch thera-
peutic regimens in order to minimize both HIV
resistance and different adverse effects of ARVs, substan-
tial improvement of information systems is mandatory
and urgently needed, as already highlighted by Grangeiro
and colleagues [36].
The improvement in survival from the first period of
HAART is undeniable and should be commended. How-
ever, results should be viewed in light of some study lim-
itations. First, the process of merging four national
databases resulted in missing data among key variables,
such as CD4+ lymphocyte counts and viral load measures.
Such limitations forced us to conduct multiple imputation
(MICE-CART) of several variables before running the sur-
vival analysis. We did not conduct MICE-CART for race,
a key variable with a significant proportion of missing in-
formation. This was a methodological and operational de-
cision: patients with private health insurance usually have
scarce information available on national datasets and our
MICE-CART could not be accurately conducted with the
available information. This problem calls for an urgent
need to provide better training of professionals and clerks
in charge of monitoring the Brazilian AIDS epidemic and
to increase the accountability and consistency of such sys-
tems. A second limitation lies in the comparison of sur-
vival across time periods of initial diagnosis. Because our
dataset is limited to 1998 to 2008, length of follow-up is
shorter for those diagnosed in 2002–2005 and 2006–2008,
limiting comparisons in survival after six to ten years fol-
lowing diagnosis. Nonetheless, these data are sufficient to
allow for comparisons of trends in survival across different
periods of diagnosis and CD4 count to AIDS diagnosis
during the early years of HAART.
Brazil has been a worldwide leader in the global efforts
to curb AIDS and to provide a standard of care andtreatment for PLWHA at no cost at the point of deliv-
ery. Notwithstanding, the concerted effort from across
different sectors of government, community leadership,
and the civil society at large may be seriously compro-
mised in the absence of a comprehensive and accurate
monitoring system. Although our analyses documented
some progress since the early years of HAART, current
levels of missing information remain unacceptably high -
a critical challenge as we enter in the third decade of the
HIV/AIDS epidemic, with more complex and costly
treatments, more patients under follow-up and more
data being collected.
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